Comparison Influence to Prognosis of CTP and MRP in AIS Patients
A legfontosabb adatok
- Hol
- Hangzhou (Kína)A helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat 18-80 év közötti, heveny ischaemiás agyi infarktusban (stroke) szenvedő felnőtteket keres, akiknek a stroke kezdete után több mint 4.5 órával agyi perfúziós vizsgálatot (CTP vagy MRP) végeznek.
- Életkor
- 18-80 év
- Nem
- Férfiak és nők is részt vehetnek.
- A betegség stádiuma
- Heveny ischaemiás stroke. Akiket a tünetek kezdete után több mint 4.5 órával vizsgálnak: az infarktusmag térfogata <70mL, a perfúziós eltérés térfogata / infarktusmag térfogata >1.2, és az abszolút mismatch >10 mL.
A részvétel fő kizáró okai
- Az rt-PA kezelést kizáró szokásos okok
- A kontrasztanyagos képalkotást kizáró okok
- A stroke előtti fogyatékosság (a stroke előtti mRS pontszám 2 vagy több)
- Más vizsgálati kutatásban való részvétel az elmúlt 30 napban
- Végstádiumú betegség, amely mellett a várható túlélés egy évnél rövidebb
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Kína
- The Second Affiliated Hospital of Zhejiang UniversityHangzhou, KínaContact: Min Lou, Ph.DRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Azonosító
- NCT03367286
- A regiszteradat frissítve
- 2022. november 23.
- Eredeti leírás
Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients within 4.5 hours after symptom onset. However, only 2% of AIS patients received thrombolytic therapy in China.A teljes eredeti leírásKevesebb
Comparison Influence to Prognosis of Computed Tomography Perfusion (CTP) and Magnetic Resonance Perfusion (MRP) in Acute Ischemic Stroke (AIS) Patients
Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients within 4.5 hours after symptom onset. However, only 2% of AIS patients received thrombolytic therapy in China.
Perfusion imaging is demonstrated to increase the rate of thrombolytic therapy by identifying the ischemic infarct core (the brain tissue that is irreversibly injured) and the ischemia penumbra (the brain tissue surrounding the ischemia infarct core that is hypoperfused but still viable) for those patients with extending therapeutic window (beyond the current 4.5 hours after symptom onset), as well as minor stroke or those with atypical symptoms.
Three prospective clinical trials, DEFUSE, DEFUSE-2 and EPITHET, has confirmed that mismatch between perfusion weighted-imaging (PWI) and diffusion weighted-imaging (DWI) correspond to the ischemic penumbra whereas DWI provides information of the ischemia infarct core and major reperfusion relate to good clinical outcome in extending therapeutic window AIS patients with DWI-PWI mismatch.
Computed tomography perfusion (CTP) may be a potential alternative technology for recognition of reversibly damaged brain tissue in AIS patients, with the prominent advantage of fast scan. Recent studies also demonstrated that CTP could select eligible candidates for reperfusion therapy. More recently, with data of EXTEND-IA, reperfusion therapy in AIS patients with CTP mismatch (using a CT time to maximum >6 s as ischemic hypoperfusion volume and a CT relative cerebral blood flow <30% of that in normal tissue as ischemic core volume) were related to good clinical outcome.
However, plenty of studies demonstrated CT cerebral blood volume did not always predict ischemic infarct core in AIS patients. A recent study also confirmed the poor contrast: noise ratios of CT cerebral blood volume and CT cerebral blood flow result in large measurement error, compared with those of diffusion weighted imaging (DWI), making it problematic to substitute DWI in selecting individual AIS patients for reperfusion treatment.
Based on those studies, it is still remained unclear whether CTP can be an alternative choice to replace magnetic resonance perfusion (MRP) in AIS patients with extending therapeutic windows. So in this study, the investigators try to determine whether baseline CTP profiles have a comparable ability to MRP in identifying patients who have a robust clinical response after early reperfusion.
Bevonási feltételek: Provision of informed consent; Male and female adults aged 18-80 years old; For patients accepting CTP or MRP over 4.5 hours after stroke onset, imaging criteria: infarct core volume <70mL, perfusion leison volume / infarct core volume >1.2, and absolute mismatch >10 mL.
Kizáró feltételek: Pre-stroke mRS score of ≥2 (indicating previous disability); Participation in any investigational study in the previous 30 days; Any terminal illness such that patient would not be expected to survive more than one-year; Standard contraindications to rt-PA; Contraindication to imaging with contrast agents.
Criteria:.